3SBio (SEHK:1530) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

1530 Overzicht aandelen

3SBio Inc. is een investeringsholding die biofarmaceutische producten ontwikkelt, produceert, op de markt brengt en verkoopt op het Chinese vasteland en internationaal.

Over het bedrijf

1530 fundamentele analyse
Sneeuwvlok Score
Waardering	5/6
Toekomstige groei	3/6
Prestaties in het verleden	2/6
Financiële gezondheid	6/6
Dividenden	2/6

Beloningen

Verhandeld tegen 61.9% onder onze schatting van de reële waarde

De winst zal naar verwachting met 14.61% per jaar groeien

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Risicoanalyse

Onstabiel dividend track record

3SBio Inc. Concurrenten

Shanghai Haohai Biological Technology

SEHK:6826

HK$15.5b

Shanghai Henlius Biotech

SEHK:2696

HK$12.3b

Shandong Boan Biotechnology

SEHK:6955

HK$5.4b

Essex Bio-Technology

SEHK:1061

HK$1.5b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor 3SBio
Historische aandelenkoersen
Huidige aandelenkoers	HK$6.87
52 Week Hoogtepunt	HK$7.69
52 Week Laag	HK$4.91
Bèta	0.68
11 maand verandering	13.37%
3 maanden verandering	7.01%
1 Jaar Verandering	6.02%
33 jaar verandering	-7.16%
5 jaar verandering	-50.65%
Verandering sinds IPO	-26.52%

Recent nieuws en updates

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

Sep 26

Recent updates

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

Sep 26

Shareholders Will Probably Hold Off On Increasing 3SBio Inc.'s (HKG:1530) CEO Compensation For The Time Being

Jun 19

An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 50% Undervalued

Nov 21

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

Sep 10

3SBio Inc. (HKG:1530) Shares Could Be 38% Below Their Intrinsic Value Estimate

Aug 22

3SBio Inc.'s (HKG:1530) Intrinsic Value Is Potentially 48% Above Its Share Price

May 21

Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly

Apr 16

What Kind Of Shareholders Hold The Majority In 3SBio Inc.'s (HKG:1530) Shares?

Mar 11

Is 3SBio Inc.'s (HKG:1530) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Feb 18

An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 38% Undervalued

Jan 31

A Look At 3SBio's (HKG:1530) Share Price Returns

Jan 03

Are Insiders Buying 3SBio Inc. (HKG:1530) Stock?

Dec 16

What Is The Ownership Structure Like For 3SBio Inc. (HKG:1530)?

Dec 01

Rendement voor aandeelhouders

	1530	HK Biotechs	HK Markt
7D	17.0%	18.3%	8.7%
1Y	6.0%	1.9%	19.7%

Rendement versus industrie: 1530 overtrof de Hong Kong Biotechs industrie, die het afgelopen jaar een rendement -1.6 % opleverde.

Rendement versus markt: 1530 presteerde slechter dan Hong Kong Market, dat het afgelopen jaar een rendement van 16.1 % opleverde.

Prijsvolatiliteit

Is 1530's price volatile compared to industry and market?
1530 volatility
1530 Average Weekly Movement	5.3%
Biotechs Industry Average Movement	7.8%
Market Average Movement	7.1%
10% most volatile stocks in HK Market	14.7%
10% least volatile stocks in HK Market	3.6%

Stabiele aandelenkoers: 1530 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van 1530 is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1993	5,607	Jing Lou	www.3sbio.com

3SBio Inc, een investeringsholding, ontwikkelt, produceert, verkoopt en verhandelt biofarmaceutische producten op het Chinese vasteland en daarbuiten. Het bedrijf levert TPIAO, een recombinant humaan trombopoëtine voor de behandeling van chemotherapie-geïnduceerde trombopenie en immuuntrombocytopenie; Cipterbin, een anti-HER2 monoklonaal antilichaam voor de behandeling van HER2-positieve uitgezaaide borstkanker; TNF, voorgevulde waterige injectieoplossing. Het biedt ook YISAIPU, de receptorfusieremmer voor tumornecrosefactor; Mandi-minoxidil tinctuur, een uitwendig OTC-geneesmiddel voor de behandeling van haaruitval; EPIAO en SEPO, een erytropoëtine-injectie; SPARIN, een injecteerbaar heparinecalcium met laag moleculair gewicht.

3SBio Inc. Samenvatting

Hoe verhouden de winst en inkomsten van 3SBio zich tot de beurswaarde?
1530 fundamentele statistieken
Marktkapitalisatie	HK$16.18b
Inkomsten(TTM)	HK$1.84b
Inkomsten(TTM)	HK$9.33b

8.8x

Koers/Winstverhouding

1.7x

P/S-verhouding

Is 1530 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
1530 resultatenrekening (TTM)
Inkomsten	CN¥8.42b
Kosten van inkomsten	CN¥1.18b
Brutowinst	CN¥7.24b
Overige uitgaven	CN¥5.58b
Inkomsten	CN¥1.66b

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	0.70
Brutomarge	85.94%
Nettowinstmarge	19.69%
Schuld/Eigen Vermogen Verhouding	24.7%

Hoe presteerde 1530 op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

3.6%

Huidig dividendrendement

34%

Uitbetalingsratio

1530 Overzicht aandelen

Beloningen

Risicoanalyse

3SBio Inc. Concurrenten

SEHK:6826

HK$15.5b

SEHK:2696

HK$12.3b

SEHK:6955

HK$5.4b

SEHK:1061

HK$1.5b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Investor sentiment improves as stock rises 22%

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

Co-Founder recently bought HK$1.5m worth of stock

First half 2024 earnings: EPS and revenues exceed analyst expectations

3SBio Inc. to Report First Half, 2024 Results on Aug 22, 2024

Upcoming dividend of HK$0.25 per share

Recent updates

Investor sentiment improves as stock rises 22%

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

Co-Founder recently bought HK$1.5m worth of stock

First half 2024 earnings: EPS and revenues exceed analyst expectations

3SBio Inc. to Report First Half, 2024 Results on Aug 22, 2024

Upcoming dividend of HK$0.25 per share

Shareholders Will Probably Hold Off On Increasing 3SBio Inc.'s (HKG:1530) CEO Compensation For The Time Being

There's Reason For Concern Over 3SBio Inc.'s (HKG:1530) Price

3Sbio Inc. Announces Management Changes

Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly

New minor risk - Dividend sustainability

3SBio Inc., Annual General Meeting, Jun 25, 2024

3SBio Inc. to Report Fiscal Year 2023 Results on Mar 20, 2024

Pinning Down 3SBio Inc.'s (HKG:1530) P/E Is Difficult Right Now

Mandi Foam of 3SBio Inc. Approves for Market Launch

These 4 Measures Indicate That 3SBio (HKG:1530) Is Using Debt Safely

Is Now The Time To Put 3SBio (HKG:1530) On Your Watchlist?

First half 2023 earnings: EPS and revenues exceed analyst expectations

Is 3SBio (HKG:1530) A Risky Investment?

First half 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.39 in 1H 2022)

3SBio Inc. to Report First Half, 2023 Results on Aug 24, 2023

Calculating The Fair Value Of 3SBio Inc. (HKG:1530)

3Sbio Inc. Announces Appointment of He Xiang as Chief Financial Officer

With EPS Growth And More, 3SBio (HKG:1530) Makes An Interesting Case

3SBio Inc. Announces Narfuraphine Hydrochloride Orally Disintegrating Tablets Co-Developed by 3Sbio Inc. and Toray in Japan Approved for Launch in the Market

Upcoming dividend of HK$0.10 per share at 1.3% yield

3SBio Inc., Annual General Meeting, Jun 20, 2023

3SBio (HKG:1530) Has A Pretty Healthy Balance Sheet

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Is Now The Time To Put 3SBio (HKG:1530) On Your Watchlist?

Now 22% undervalued

Is 3SBio Inc. (HKG:1530) Trading At A 23% Discount?

3SBio Inc. Announces Resignation of Tang Ke as Non-Executive Director

3Sbio Inc. Announces Executive Changes

Do 3SBio's (HKG:1530) Earnings Warrant Your Attention?

Less than half of directors are independent

Investor sentiment improved over the past week

We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease

Investor sentiment improved over the past week

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

3SBio Inc. (HKG:1530) Shares Could Be 49% Below Their Intrinsic Value Estimate

First half 2022 earnings released: EPS: CN¥0.39 (vs CN¥0.35 in 1H 2021)

3SBio Inc. to Report Q2, 2022 Results on Aug 24, 2022

3SBio Inc. Approves Final Dividend for the Year Ended 31 December 2021

Upcoming dividend of HK$0.20 per share

3Sbio Inc. Announces Phase III Clinical Study of It's Recombinant Human Thrombopoietin (Rhtpo) Injection (Tpiao )

Full year 2021 earnings: EPS exceeds analyst expectations

Less than half of directors are independent

Is 3SBio Inc. (HKG:1530) Trading At A 45% Discount?

3SBio Inc., Annual General Meeting, Jun 22, 2022

We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease

Full year 2021 earnings: EPS exceeds analyst expectations

3Sbio Inc. Proposes Final Cash Dividend for the Year Ended 31 December 2021, Payable on or around 11 July 2022

Investor sentiment improved over the past week

3SBio Inc. Provides Earnings Guidance for the Year Ended 31 December 2021

We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease

An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 50% Undervalued

First half 2021 earnings released: EPS CN¥0.35 (vs CN¥0.28 in 1H 2020)

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt